RECENT NEWS

Cambridge scientists have developed an artificially-intelligent tool capable of predicting in four cases out of five whether people with early signs of dementia will remain stable or develop Alzheimer’s disease.

A new report from IBMS and Abbott, ‘Community Diagnostics: Scaling Point-of-Care Testing for Patient-Centred Outcomes’ provides a POCT roadmap for the new government, healthcare organisations and primary care providers.

London pathology services provider Synnovis is continuing to recover services following the cyber attack on 3 June.

Sophia Genetics has announced that OncoHelix, an internationally recognised research and diagnostics laboratory for precision diagnostics, will implement MSK-ACCESS powered with SOPHiA DDM. The organisation, which currently uses the SOPHiA DDM platform for myeloid testing, will use the new liquid biopsy solution to advance its oncology testing capabilities.

BD (Becton Dickinson) and Quest Diagnostics have announced a global collaboration agreement to develop, manufacture and commercialise flow cytometry-based companion diagnostics (CDx) intended to help select the best treatment for patients with cancer and other diseases.

Proscia has introduced the next version of its enterprise pathology platform Concentriq AP. The release includes new functionality that advances the impact of AI in shaping pathologists’ understanding of four of the top five most common cancers worldwide.

The Institute of Biomedical Science (IBMS) has backed the conclusions and recommendations from the UK COVID-19 Inquiry’s first report, which include comprehensive and multidisciplinary planning, the involvement of a broader range of experts and a new independent statutory body responsible for whole system preparedness and response,

The next Pro-Lab Diagnostics scientific webinar will be ‘The second 5-year national antimicrobial resistance action plan: what's new’. An update on the UK’s 20-year vision for confronting antimicrobial resistance, it takes place on Tuesday 30 July, 12 noon – 1.00 pm.

In a collaborative project led by the University of Oxford, diagnostic artificial intelligence (AI) applications from Paige are being trialled as part of a live, multisite clinical use study to evaluate AI in the diagnosis of prostate cancer within the NHS.

The Chair of the UK Covid-19 Inquiry, Baroness Heather Hallett, is urging the new UK government and the governments of Wales, Scotland and Northern Ireland to implement promptly her 10 key recommendations following publication of the Inquiry’s report of its first investigation into the nation’s resilience and preparedness for the pandemic.

The UK will become the first country in the world to have a national programme that uses the same vaccine to protect newborns and also older adults against respiratory syncytial virus (RSV).

Beckman Coulter Diagnostics has announced a €10 million investment for its manufacturing and research base in County Clare, Ireland, that underscores its commitment to innovation and growth in the region.

In a study recently published in the renowned journal Allergy, a MedUni Vienna research team shows that COVID-19 leads to considerable long-term changes in the immune system, even in mild cases. The findings could help to better understand the long-term consequences of an infection with SARS-CoV-2.

Pioneering scientists were awarded the MRC Impact Prize to celebrate their achievements alongside those of the 2023 MRC Millennium Medal recipient.

Danaher Corporation has launched a research collaboration with Stanford University's Department of Bioengineering intended to shape the future of cancer drug screening through ‘smart microscopy’. Combining spatial biology with artificial intelligence (AI), the research team at the Danaher Beacon for Spatialomics aims to help de-risk cancer drug development.

ALZpath has signed a licensing agreement with Beckman Coulter Diagnostics for use of its best-in-class ALZpath pTau217 antibody in a blood-based in vitro diagnostic (IVD) test on the DxI 9000 Immunoassay Analyzer to advance Alzheimer's disease diagnosis.

French startup Bioptimus has announced the release of H-optimus-0, which the company says is the world’s largest open-source AI foundation model for pathology. With 1.1 billion parameters, H-optimus-0 is trained on a proprietary dataset of several hundreds of millions of images extracted from over 500,000 histopathology slides across 4,000 clinical practices.

Philips IntelliSite Pathology Solution 5.1 has received 510(k) clearance from the US Food and Drug Administration. Philips was first to market an FDA-approved digital pathology solution in 2017 and is the most widely deployed digital pathology solution for primary diagnosis around the world.

To help accelerate research into new treatments for acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), Thermo Fisher Scientific is partnering with the National Cancer Institute (NCI) – part of the US National Institutes of Health – on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial.

Innovate UK has awarded four UK companies a share of £4 million funding through Contracts for Innovation to support innovative research into dementia diagnosis.